Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
NCT ID: NCT06234098
Last Updated: 2025-05-02
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
85 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-02-13
Study Completion Date
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of AT-1965 in patients with advanced, refractory or recurrent solid tumors (nonresectable and/or metastatic) including mTNBC.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
NCT04855656
Advanced Solid Tumor
RECRUITING
PHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06488716
Solid Tumour
TERMINATED
PHASE1
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
NCT06403436
Advanced Solid Tumor
Adult Solid Tumor
Adult Disease
+5 more
RECRUITING
PHASE1
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
NCT02503423
Solid Tumors
Lymphoma
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
NCT04975958
Locally Advanced Solid Tumor
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Solid Tumor
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AT-1965 Liposome Injection
Group Type
EXPERIMENTAL
AT-1965 Liposome Injection
Intervention Type
DRUG
AT-1965 Liposome Injection administered intravenously once weekly for the first 3 weeks (Days 1, 8 and 15) of a 4 week cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AT-1965 Liposome Injection
AT-1965 Liposome Injection administered intravenously once weekly for the first 3 weeks (Days 1, 8 and 15) of a 4 week cycle.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The patient has a histologically or cytologically confirmed unresectable or metastatic solid tumor that is refractory to standard therapy or for which in the opinion of the investigator no standard therapy is suitable.
2. Patient should have at least 1 measurable lesion per RECIST version 1.1 as assessed by the investigator. For Part A only, patients with radiographically evaluable but non-measurable disease are allowed after discussion with the sponsor.
3. Recovered from AEs (except irAEs) of prior chemotherapy (per NCI CTCAE version 5.0) to Grade ≤ 1 or return to baseline status (except for alopecia) as per Investigator's discretion.
4. The patient has an ECOG performance status of 0 to 2.
5. The patient has adequate bone marrow, renal, and hepatic function, defined as follows:
1. Hemoglobin ≥9.5 g/dL (without transfusion in the prior 3 weeks).
2. Platelets ≥100 × 109 cells/L (may be achieved with transfusion as per PI discretion)
3. ANC ≥1.5 ×109 cells/L (without the use of hematopoietic growth factors within 4 weeks prior to dosing).
4. Creatinine Clearance ≥60 mL/min (by using Cockcroft-gault equation)
5. Total bilirubin ≤1.5 × ULN, unless the patient has a prior history of Gilbert's syndrome, in which case ≤3.0 × ULN is acceptable.
6. AST and ALT ≤2.5 × ULN; or ≤5 × ULN if due to liver involvement by tumor
6. Female patients of child-bearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of study drug and before each start of a new treatment cycle. NOTE: Women are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause) and have an elevated follicle-stimulating hormone (FSH) at screening.
7. Female patients of childbearing potential must agree to use a highly effective method of contraception during the study and for a minimum of 3 months following administration of study drug, which includes a barrier method plus 1 or more of the following:
1. Hormonal contraceptives (e.g., birth control pills, skin patches, vaginal rings, or the Depo-Provera® shot)
2. Intrauterine device (IUD)
3. Male or female condoms with spermicide
4. Diaphragm with spermicide
5. Permanent tubal occlusive birth control system
8. Male patients with female partners of childbearing potential must be vasectomized or be willing to use an acceptable method of birth control or to practice abstinence during the study and for 3 months after the last dose of IMP.
9. Must be 30 days since participation in any other interventional clinical trial.
10. Must be 28 days since mRNA Covid 19 vaccine injection.
11. Willing to avoid sun exposure, wear protective clothing, and/or apply broad spectrum (ultraviolet A \[UVA\] and ultraviolet B \[UVB\] protection) sunscreen if sun exposure is unavoidable.
12. The patient is capable of understanding the written informed consent, provides signed and witnessed written informed consent and authorization permitting use of collected tissue and personal health information, and agrees to comply with protocol requirements.
For Part B Dose Expansion in TNBC only:
1. Histologically or cytologically confirmed metastatic triple-negative breast cancer (mTNBC) who had received at least two prior treatments (a taxane and sacituzumab govitecan-hziy) for metastatic disease, for advanced disease.
2. In addition, patients with TNBC with either Low HER2 (IHC 1+ or IHC 2+/in situ hybridization-negative), PD-L1 (CPS\>10) or BRCA mutation need to have prior FDA approved available therapies before participation in this expansion arm.
2. Patient should have at least 1 measurable lesion per RECIST version 1.1 as assessed by the investigator. For Part A only, patients with radiographically evaluable but non-measurable disease are allowed after discussion with the sponsor.
3. Recovered from AEs (except irAEs) of prior chemotherapy (per NCI CTCAE version 5.0) to Grade ≤ 1 or return to baseline status (except for alopecia) as per Investigator's discretion.
4. The patient has an ECOG performance status of 0 to 2.
5. The patient has adequate bone marrow, renal, and hepatic function, defined as follows:
1. Hemoglobin ≥9.5 g/dL (without transfusion in the prior 3 weeks).
2. Platelets ≥100 × 109 cells/L (may be achieved with transfusion as per PI discretion)
3. ANC ≥1.5 ×109 cells/L (without the use of hematopoietic growth factors within 4 weeks prior to dosing).
4. Creatinine Clearance ≥60 mL/min (by using Cockcroft-gault equation)
5. Total bilirubin ≤1.5 × ULN, unless the patient has a prior history of Gilbert's syndrome, in which case ≤3.0 × ULN is acceptable.
6. AST and ALT ≤2.5 × ULN; or ≤5 × ULN if due to liver involvement by tumor
6. Female patients of child-bearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of study drug and before each start of a new treatment cycle. NOTE: Women are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause) and have an elevated follicle-stimulating hormone (FSH) at screening.
7. Female patients of childbearing potential must agree to use a highly effective method of contraception during the study and for a minimum of 3 months following administration of study drug, which includes a barrier method plus 1 or more of the following:
1. Hormonal contraceptives (e.g., birth control pills, skin patches, vaginal rings, or the Depo-Provera® shot)
2. Intrauterine device (IUD)
3. Male or female condoms with spermicide
4. Diaphragm with spermicide
5. Permanent tubal occlusive birth control system
8. Male patients with female partners of childbearing potential must be vasectomized or be willing to use an acceptable method of birth control or to practice abstinence during the study and for 3 months after the last dose of IMP.
9. Must be 30 days since participation in any other interventional clinical trial.
10. Must be 28 days since mRNA Covid 19 vaccine injection.
11. Willing to avoid sun exposure, wear protective clothing, and/or apply broad spectrum (ultraviolet A \[UVA\] and ultraviolet B \[UVB\] protection) sunscreen if sun exposure is unavoidable.
12. The patient is capable of understanding the written informed consent, provides signed and witnessed written informed consent and authorization permitting use of collected tissue and personal health information, and agrees to comply with protocol requirements.
For Part B Dose Expansion in TNBC only:
1. Histologically or cytologically confirmed metastatic triple-negative breast cancer (mTNBC) who had received at least two prior treatments (a taxane and sacituzumab govitecan-hziy) for metastatic disease, for advanced disease.
2. In addition, patients with TNBC with either Low HER2 (IHC 1+ or IHC 2+/in situ hybridization-negative), PD-L1 (CPS\>10) or BRCA mutation need to have prior FDA approved available therapies before participation in this expansion arm.
Exclusion Criteria
1. The patient has an uncontrolled or life-threatening, symptomatic, current or recurrent disease (e.g., cardiovascular, renal, hepatic, endocrine) or other abnormality that could affect the action, absorption, or disposition of the study drug, may impact the ability of the patient to participate, may affect clinical or laboratory assessments, or otherwise has the potential to confound the study results.
2. Unstable or severe uncontrolled medical condition (e.g., unstable cardiac function, unstable pulmonary condition) or any important medical or psychiatric illness or abnormal laboratory finding that would, in the Investigator's judgment, increase the risk to the patient associated with his or her participation in the study.
3. Uncontrolled diabetes.
4. Patients with a history of autoimmune disease. Excluded autoimmune conditions are listed in Appendix 1.
1. Patients with history of transient autoimmune manifestations of an acute infectious disease that resolved upon treatment of the infectious agent are not excluded (e.g. acute Lyme arthritis).
2. Please contact the medical monitor regarding any uncertainty over autoimmune exclusions.
5. History of interstitial lung disease, idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on chest computed tomography scan in the last 6 months; NOTE: history of radiation pneumonitis in the radiation field (fibrosis) is permitted.
6. History of hemolysis or hemolytic anemia.
7. Evidence of ongoing subclinical hemolysis (high LDH and low serum haptoglobin with increased reticulocyte count).
8. History of adrenal gland disorders such as Cushing Syndrome, Congenital adrenal hyperplasia, Addison's Disease and hyperaldosteronism
9. Recipient of an allogeneic bone marrow transplantation or solid organ transplantation.
10. Endocrinopathy, unless on stable hormone replacement therapy.
11. History of known human immunodeficiency virus (HIV); unresolved viral hepatitis as documented by the detection of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody at the time of the screening visit, and known quantitative HCV RNA results greater than the lower limits of detection of the assay.
12. Clinically significant cardiovascular disease including:
* Myocardial infarction or stroke within 6 months prior to the initiation of study treatment.
* LVEF \<50% on baseline assessment.
* If patient enrolled with cardiovascular disease, the LVEF must be confirmed at screening by and echocardiogram or MUGA.
* Unstable angina within 6 months prior to the initiation of study treatment.
* Congestive heart failure or cardiomyopathy with New York Heart Association Class 2, 3 or 4 by clinical assessment or by imaging studies within 6 months prior to the initiation of study treatment.
* Coronary or peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism (in past 3 months).
* History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes).
* Uncontrolled hypertension where the Systolic is ≥150 mmHg and the diastolic blood pressure ≥110 mm Hg despite ongoing antihypertensive therapy.
* QT interval corrected by the Fridericia correction formula (QTcF) ≥470 msec on the Screening ECG.
* The patient has cardiac dysrhythmias.
* The patient requires the use of concomitant medications that prolong QT/QTc interval (except the patients who have normal ECG but are taking medications that prolong QT/QTc interval).
13. Recent anticancer treatment, including the following (patient may be started earlier within these timeframes if considered by the Investigator to be safe and within the best interest of the patient and with approval from the Sponsor):
* Systemic antineoplastic therapy within 21 days or 5 half-lives prior to initiation of study treatment. (6 weeks for nitrosoureas or mitomycin C and 8 weeks for platinum based drugs) and/or has not recovered from acute toxicity for the most recent antitumor treatment to CTCAE Grade 1 or baseline, except for alopecia, prior to the first dose of study drug.
* Radiation therapy within 2 weeks prior to the initiation of study treatment
* Patient received chemoembolization or radioembolization within 4 weeks prior to the initiation of study treatment.
14. The patient has received any investigational agents that have not received regulatory approval within 30 days or 5 half-lives prior to the first dose of study drug, whichever is shorter. This includes the FDA approved for all Emergency Authorization Use (EAU) drugs or therapies.
15. Major surgery within 4 weeks of starting study treatment or not recovered from any effects of prior major surgery (uncomplicated central line placement or fine needle aspirate are not considered major surgery).
16. Primary tumor type:
* Central nervous system (CNS) malignant disease not previously treated, active leptomeningeal disease, uncontrolled symptomatic CNS involvement, or CNS malignant disease requiring steroid or other therapeutic intervention.
* Liquid/hematological tumors
* Lymphoma
* Uveal melanoma
17. Patients with a history of secondary malignancy(ies) that is currently clinically significant and has potential for metastases or currently requires active intervention (except for gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LH-RH) agonists in prostate cancer or hormonal therapy in breast cancer).
* Secondary malignancies exceptions include basal cell or squamous cell skin cancer
18. Requires systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to Day 1 of treatment. Inhaled, intranasal, intra-articular and topical (including ocular) steroids are allowed. Adrenal replacement (i.e., physiologic replacement) doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
19. History of severe immune-related AE (irAE) that led to permanent discontinuation of prior immunotherapy.
20. History of Grade ≥ 3 irAE within the past 16 weeks or any Grade 4 life threatening irAE (regardless of duration) or neurologic or ocular AE of any grade while receiving prior immunotherapy; NOTE: Patients with endocrine AEs of any grade are permitted to enroll if they are stably maintained on appropriate replacement therapy but must have no history of adrenal crisis and be asymptomatic.
21. Has, within 28 days prior to screening, received a live, attenuated or mRNA based vaccine against infectious disease.
22. Nursing women not willing to stop breastfeeding while on study and for 3 months thereafter.
23. Uncontrolled active infection requiring intravenous (IV) antibiotic, antiviral, or antifungal medications within 14 days prior to first dose of study treatment. Patients on chronic suppressive antibiotics may be allowed after discussion with the Sponsor.
24. Patient is \<18 years of age at the time of informed consent.
25. Life expectancy of \<3 months.
26. Known current drug or alcohol abuse.
27. The patient is not an appropriate candidate for participation in this clinical study for any other reason as deemed by the investigator.
2. Unstable or severe uncontrolled medical condition (e.g., unstable cardiac function, unstable pulmonary condition) or any important medical or psychiatric illness or abnormal laboratory finding that would, in the Investigator's judgment, increase the risk to the patient associated with his or her participation in the study.
3. Uncontrolled diabetes.
4. Patients with a history of autoimmune disease. Excluded autoimmune conditions are listed in Appendix 1.
1. Patients with history of transient autoimmune manifestations of an acute infectious disease that resolved upon treatment of the infectious agent are not excluded (e.g. acute Lyme arthritis).
2. Please contact the medical monitor regarding any uncertainty over autoimmune exclusions.
5. History of interstitial lung disease, idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on chest computed tomography scan in the last 6 months; NOTE: history of radiation pneumonitis in the radiation field (fibrosis) is permitted.
6. History of hemolysis or hemolytic anemia.
7. Evidence of ongoing subclinical hemolysis (high LDH and low serum haptoglobin with increased reticulocyte count).
8. History of adrenal gland disorders such as Cushing Syndrome, Congenital adrenal hyperplasia, Addison's Disease and hyperaldosteronism
9. Recipient of an allogeneic bone marrow transplantation or solid organ transplantation.
10. Endocrinopathy, unless on stable hormone replacement therapy.
11. History of known human immunodeficiency virus (HIV); unresolved viral hepatitis as documented by the detection of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody at the time of the screening visit, and known quantitative HCV RNA results greater than the lower limits of detection of the assay.
12. Clinically significant cardiovascular disease including:
* Myocardial infarction or stroke within 6 months prior to the initiation of study treatment.
* LVEF \<50% on baseline assessment.
* If patient enrolled with cardiovascular disease, the LVEF must be confirmed at screening by and echocardiogram or MUGA.
* Unstable angina within 6 months prior to the initiation of study treatment.
* Congestive heart failure or cardiomyopathy with New York Heart Association Class 2, 3 or 4 by clinical assessment or by imaging studies within 6 months prior to the initiation of study treatment.
* Coronary or peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism (in past 3 months).
* History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes).
* Uncontrolled hypertension where the Systolic is ≥150 mmHg and the diastolic blood pressure ≥110 mm Hg despite ongoing antihypertensive therapy.
* QT interval corrected by the Fridericia correction formula (QTcF) ≥470 msec on the Screening ECG.
* The patient has cardiac dysrhythmias.
* The patient requires the use of concomitant medications that prolong QT/QTc interval (except the patients who have normal ECG but are taking medications that prolong QT/QTc interval).
13. Recent anticancer treatment, including the following (patient may be started earlier within these timeframes if considered by the Investigator to be safe and within the best interest of the patient and with approval from the Sponsor):
* Systemic antineoplastic therapy within 21 days or 5 half-lives prior to initiation of study treatment. (6 weeks for nitrosoureas or mitomycin C and 8 weeks for platinum based drugs) and/or has not recovered from acute toxicity for the most recent antitumor treatment to CTCAE Grade 1 or baseline, except for alopecia, prior to the first dose of study drug.
* Radiation therapy within 2 weeks prior to the initiation of study treatment
* Patient received chemoembolization or radioembolization within 4 weeks prior to the initiation of study treatment.
14. The patient has received any investigational agents that have not received regulatory approval within 30 days or 5 half-lives prior to the first dose of study drug, whichever is shorter. This includes the FDA approved for all Emergency Authorization Use (EAU) drugs or therapies.
15. Major surgery within 4 weeks of starting study treatment or not recovered from any effects of prior major surgery (uncomplicated central line placement or fine needle aspirate are not considered major surgery).
16. Primary tumor type:
* Central nervous system (CNS) malignant disease not previously treated, active leptomeningeal disease, uncontrolled symptomatic CNS involvement, or CNS malignant disease requiring steroid or other therapeutic intervention.
* Liquid/hematological tumors
* Lymphoma
* Uveal melanoma
17. Patients with a history of secondary malignancy(ies) that is currently clinically significant and has potential for metastases or currently requires active intervention (except for gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LH-RH) agonists in prostate cancer or hormonal therapy in breast cancer).
* Secondary malignancies exceptions include basal cell or squamous cell skin cancer
18. Requires systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to Day 1 of treatment. Inhaled, intranasal, intra-articular and topical (including ocular) steroids are allowed. Adrenal replacement (i.e., physiologic replacement) doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
19. History of severe immune-related AE (irAE) that led to permanent discontinuation of prior immunotherapy.
20. History of Grade ≥ 3 irAE within the past 16 weeks or any Grade 4 life threatening irAE (regardless of duration) or neurologic or ocular AE of any grade while receiving prior immunotherapy; NOTE: Patients with endocrine AEs of any grade are permitted to enroll if they are stably maintained on appropriate replacement therapy but must have no history of adrenal crisis and be asymptomatic.
21. Has, within 28 days prior to screening, received a live, attenuated or mRNA based vaccine against infectious disease.
22. Nursing women not willing to stop breastfeeding while on study and for 3 months thereafter.
23. Uncontrolled active infection requiring intravenous (IV) antibiotic, antiviral, or antifungal medications within 14 days prior to first dose of study treatment. Patients on chronic suppressive antibiotics may be allowed after discussion with the Sponsor.
24. Patient is \<18 years of age at the time of informed consent.
25. Life expectancy of \<3 months.
26. Known current drug or alcohol abuse.
27. The patient is not an appropriate candidate for participation in this clinical study for any other reason as deemed by the investigator.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CBCC Global Research
NETWORK
Sponsor Role
collaborator
Alyssum Therapeutics
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard Fahrner, PhD
Role: STUDY_DIRECTOR
Alyssum Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CBCC Global Research Site 001
Scottsdale, Arizona, United States
Site Status
RECRUITING
CBCC Global Research Site 005
Bakersfield, California, United States
Site Status
RECRUITING
CBCC Global Research Site 007
El Segundo, California, United States
Site Status
RECRUITING
CBCC Global Research Site 008
Santa Monica, California, United States
Site Status
RECRUITING
CBCC Global Research Site 003
Stanford, California, United States
Site Status
RECRUITING
CBCC Global Research Site 002
Portland, Oregon, United States
Site Status
RECRUITING
CBCC Global Research Site 006
Dallas, Texas, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AT-1965-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors
NCT04678921
COMPLETED
PHASE1
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT04250155
ACTIVE_NOT_RECRUITING
PHASE1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960
ACTIVE_NOT_RECRUITING
PHASE1
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT04196257
RECRUITING
PHASE1
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
NCT02650713
COMPLETED
PHASE1
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
NCT06902350
RECRUITING
PHASE1
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
NCT05075564
COMPLETED
PHASE1
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
NCT01421524
COMPLETED
PHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05487235
COMPLETED
PHASE1
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT02410512
COMPLETED
PHASE1
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
NCT05121948
TERMINATED
PHASE1
SMP-3124LP in Adults With Advanced Solid Tumors
NCT06526819
RECRUITING
PHASE1/PHASE2
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
NCT04642365
TERMINATED
PHASE1
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
NCT01078649
COMPLETED
PHASE1
A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors
NCT01090960
COMPLETED
PHASE1
A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors
NCT02243917
TERMINATED
PHASE1
Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017
NCT04144842
COMPLETED
PHASE1
A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors
NCT01345201
COMPLETED
PHASE1
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
NCT01041235
COMPLETED
PHASE1
Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors
NCT02508441
TERMINATED
PHASE1
Study of LP-184 in Patients With Advanced Solid Tumors
NCT05933265
RECRUITING
PHASE1/PHASE2
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029
RECRUITING
PHASE1
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
NCT02517398
COMPLETED
PHASE1
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
NCT03352531
COMPLETED
PHASE1